<DOC>
	<DOC>NCT01354457</DOC>
	<brief_summary>The purpose of this study is to determine whether fractionated RIT with Epratuzumab and radiolabeled Epratuzumab are effective in the treatment of relapsing or refractory ALL.</brief_summary>
	<brief_title>Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<criteria>Age 1870 years BALL (OMS) with &gt;=20% of blasts in bone marrow CD22+ expression &gt;=70% of the blast population All previously treated ALL patients who have experienced relapse or treatment failure At least 15 days since previous treatment Performance status 0 2 Creatinine clearance &gt;= 50 ml/min (Cockroft formula). Serum bilirubin &lt;= 30 mmol/l Written informed consent TALL Meningeal involvement CD22 expression on tumor cells or &lt; 70% HIV positive Active Hepatitis B or C Active infection within 7 days of starting treatment Left ventricular ejection fraction &lt; 50%. Contraindication to 90YDOTAhLL2 Previous or concurrent second malignancy except for adequately treated basal cell carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively treated solid cancer, with no evidence of disease for at least 5 years Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and followup schedule Participation at the same time in another study in which investigational drugs are used Absence of written informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Patient with relapsing or refractory CD22+B-acute lymphoblastic leukemia (ALL)</keyword>
</DOC>